Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response.
Semin Ophthalmol
; 37(2): 164-170, 2022 Feb 17.
Article
in En
| MEDLINE
| ID: mdl-34384329
ABSTRACT
PURPOSE:
This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response.METHODS:
This study included 14 eyes of 13 patients (mean age 65.7 ± 5.2 years) with DME, and eligible eyes underwent single intravitreal injection of 0.025 mg fasudil. The best-corrected visual acuity (BCVA), intraocular pressure (IOP), and central macular thickness (CMT) were evaluated before and 1, 2, and 3 months after treatment. The standard automated perimetry (SAP) results and maximal response of the electroretinogram (ERG) were recorded before and 3 months after treatment.RESULTS:
The BCVA, IOP, and CMT remained unchanged during the study period. Similarly, the mean deviation obtained by SAP and each ERG parameter did not show significant changes after the treatment.CONCLUSIONS:
Although single intravitreal fasudil injection failed to show therapeutic benefits in DME, it seemed to have no negative effect on the retina.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Macular Edema
/
Diabetes Mellitus
/
Diabetic Retinopathy
Type of study:
Diagnostic_studies
/
Etiology_studies
Limits:
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
Semin Ophthalmol
Journal subject:
OFTALMOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Japan